MX2011007313A - Derivados de desoxiactagardina. - Google Patents

Derivados de desoxiactagardina.

Info

Publication number
MX2011007313A
MX2011007313A MX2011007313A MX2011007313A MX2011007313A MX 2011007313 A MX2011007313 A MX 2011007313A MX 2011007313 A MX2011007313 A MX 2011007313A MX 2011007313 A MX2011007313 A MX 2011007313A MX 2011007313 A MX2011007313 A MX 2011007313A
Authority
MX
Mexico
Prior art keywords
deoxyactagardine
infection
derivatives
difficile
compounds
Prior art date
Application number
MX2011007313A
Other languages
English (en)
Inventor
Sjoerd Nicolaas Wadman
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of MX2011007313A publication Critical patent/MX2011007313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

La presente invención pertenece en general a ciertos compuestos de la desoxiactagardina tipo A y B. Tales compuestos son adecuados para el uso en el tratamiento de infecciones microbianas, por ejemplo infección por Clostridium, tales como C. perfringens, C. difficile, C. tetani, y/o C. botulinum, en particular C. difficile, especialmente infección del colon y/o el intestino grueso y la diarrea asociada con la infección microbiana.
MX2011007313A 2009-01-14 2010-01-12 Derivados de desoxiactagardina. MX2011007313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14449009P 2009-01-14 2009-01-14
PCT/GB2010/000042 WO2010082018A1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Publications (1)

Publication Number Publication Date
MX2011007313A true MX2011007313A (es) 2011-08-04

Family

ID=42110329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007313A MX2011007313A (es) 2009-01-14 2010-01-12 Derivados de desoxiactagardina.

Country Status (22)

Country Link
US (2) US8283371B2 (es)
EP (1) EP2387580B1 (es)
JP (1) JP5719312B2 (es)
KR (1) KR20110119699A (es)
CN (1) CN102348718B (es)
AU (1) AU2010205472B2 (es)
CA (1) CA2749278A1 (es)
DK (1) DK2387580T3 (es)
EA (1) EA021683B1 (es)
ES (1) ES2520165T3 (es)
HR (1) HRP20141084T1 (es)
IL (1) IL213927A0 (es)
MX (1) MX2011007313A (es)
NZ (1) NZ594011A (es)
PL (1) PL2387580T3 (es)
PT (1) PT2387580E (es)
RS (1) RS53586B1 (es)
SG (1) SG172944A1 (es)
SI (1) SI2387580T1 (es)
TW (1) TWI453029B (es)
WO (1) WO2010082018A1 (es)
ZA (1) ZA201104991B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
EP2387580B1 (en) 2009-01-14 2014-08-13 Novacta Biosystems Limited Deoxyactagardine derivatives
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013509D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) * 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (es) * 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
DE69433357T2 (de) * 1994-09-12 2004-09-09 Aventis Pharma Deutschland Gmbh Rekombinantes Mersacidin und Verfahren zu seiner Herstellung
AU713050B2 (en) 1995-06-23 1999-11-25 Ambi Inc. A method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) * 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
CN1321628C (zh) 2000-06-28 2007-06-20 史密斯克莱·比奇曼公司 湿磨方法
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
WO2004033706A2 (en) 2002-10-10 2004-04-22 Molichem Medicines, Inc. Nucleic acids encoding duramycin
EP1646646B1 (en) 2003-07-18 2007-03-07 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof.
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
CA2623624A1 (en) 2005-09-27 2007-04-05 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
WO2008050209A1 (en) 2006-10-27 2008-05-02 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
WO2008151434A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
CN102224164A (zh) 2008-11-24 2011-10-19 森蒂内拉制药公司 具有改进的抗菌活性的羊毛硫抗生素酰胺衍生物
EP2387580B1 (en) 2009-01-14 2014-08-13 Novacta Biosystems Limited Deoxyactagardine derivatives
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体

Also Published As

Publication number Publication date
PL2387580T3 (pl) 2015-01-30
ZA201104991B (en) 2013-10-31
IL213927A0 (en) 2011-07-31
WO2010082018A1 (en) 2010-07-22
EA021683B1 (ru) 2015-08-31
EP2387580A1 (en) 2011-11-23
EP2387580B1 (en) 2014-08-13
AU2010205472B2 (en) 2013-03-14
RS53586B1 (en) 2015-02-27
PT2387580E (pt) 2014-10-30
AU2010205472A1 (en) 2011-07-28
TWI453029B (zh) 2014-09-21
JP2012515195A (ja) 2012-07-05
US8741945B2 (en) 2014-06-03
KR20110119699A (ko) 2011-11-02
US20100179207A1 (en) 2010-07-15
EA201190071A1 (ru) 2012-06-29
CN102348718A (zh) 2012-02-08
CN102348718B (zh) 2015-06-03
CA2749278A1 (en) 2010-07-22
DK2387580T3 (da) 2014-10-13
JP5719312B2 (ja) 2015-05-13
US8283371B2 (en) 2012-10-09
NZ594011A (en) 2013-12-20
HRP20141084T1 (hr) 2015-02-13
SI2387580T1 (sl) 2014-11-28
US20120277145A1 (en) 2012-11-01
TW201029661A (en) 2010-08-16
ES2520165T3 (es) 2014-11-11
SG172944A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
MX2011007313A (es) Derivados de desoxiactagardina.
PH12018501711A1 (en) Compounds for treating spinal muscular atrophy
MX2020002727A (es) Nuevo uso para tratamiento de infecciones por clostridium difficile.
WO2010063996A3 (en) Antibacterial compounds
GEP20135964B (en) Inhibitors of beta-secretase
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX2014010406A (es) Compuestos para tratar atrofia muscular espinal.
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
PH12015501393A1 (en) Pesticidal compositions and processes related thereto
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
NZ597517A (en) 5-fluoropyrimidinone derivatives
WO2012030535A3 (en) Bacteriophage lytic enzymes as alternative antimicrobials
MX2011006803A (es) Agentes antibacterianos novedosos para el tratamiento de infecciones gram positivas.
MY160677A (en) Fermented infant formula
IN2012DN02210A (es)
PH12014502383A1 (en) Compounds for use as inhibitors of alternative oxidase or cytochrome bc1 complex
EP2575452A4 (en) ANTIMICROBIAL COMPOSITIONS
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX2013002262A (es) Espesante asociativo para preparaciones acuosas.
WO2012037116A3 (en) Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof
WO2011029536A3 (de) Verwendung von cyclischen ketoenolen gegen pflanzenpathogene bakterien
MX2012004282A (es) Composiciones farmaceuticas.
CO6680629A2 (es) Compuestos con actividad antibacteriana contra clsotridium
MX2011010046A (es) Derivados de diaminopteridina.
CY1115699T1 (el) Παραγωγα της δεοξυακταγαρδινης

Legal Events

Date Code Title Description
FG Grant or registration